Investor Relations Overview
NeoGenomics, Inc. is a high-complexity CLIA—certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. For additional information about NeoGenomics, visit neogenomics.com.
The stock information provided is for informational purposes only and is not intended for trading purposes. The stock information is provided by eSignal, stock charts are provided by EDGAR Online, both third party services, and NeoGenomics does not maintain or provide information directly to this service. Stock information is delayed approximately 20 minutes.
Company Overview Presentation
Download our Company Overview
Second Quarter 2016 Earnings Release
2016 07 26 neo genomics q2 2016 earnings release - final from NeoGenomics Laboratory | Cancer Diagnostics
View all » Financial News